Skip to main content

About OBRI

The Observational and Best Practices Research Initiative (OBRI-PsA)

A longitudinal observational registry collecting real-world clinical and patient-reported data from individuals living with psoriatic arthritis across Ontario.

About the Registry

The OBRI-PsA is a longitudinal observational registry that collects real-world clinical and patient-reported data from individuals living with psoriatic arthritis (PsA) across Ontario. The first patient was enrolled on February 14, 2022.

Psoriatic arthritis is a chronic inflammatory condition affecting the joints and skin, typically in people who have psoriasis. It can cause pain, stiffness, and swelling in joints throughout the body, and can significantly impact quality of life and ability to work.

Although effective treatments exist, the real-world effectiveness and long-term outcomes of these treatments in diverse patient populations are not well understood. The OBRI-PsA was created to fill that gap, complementing the established OBRI rheumatoid arthritis registry.

Registry Objectives

  • Describe patterns of treatment and health care utilization among patients with PsA in Ontario
  • Evaluate the real-world effectiveness and safety of biologic and targeted synthetic DMARDs in PsA
  • Identify predictors of treatment response, remission, and disease flare in PsA
  • Examine the impact of comorbidities on PsA outcomes and treatment decisions
  • Generate evidence to inform provincial drug policy for PsA in Canada

What Participation Involves

Participants in the OBRI-PsA complete interviews at enrollment and at regular follow-up intervals. These interviews capture information about symptoms, medications, quality of life, and overall health. Your rheumatologist also contributes information from your clinic visits.

Participation does not change your medical care in any way and can be done from home by phone or online.